3 transcripts
NTRA
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
on today's call. First, I want to flag that the ALTAIR investigators let us know that they are not going to make the time line for the submission to ESMO
NTRA
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
patients, the MRD-positive arm of the trial, which is investigating the efficacy of Genentech's atezolizumab, drug versus placebo is expected to read
NTRA
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
.
Interestingly, the investigators also presented preliminary results from the Phase II TAS-102 substudy, which enrolled 13 patients to receive TAS
- Prev
- 1
- Next